Biotech in China
What China's health-tech surge means for global health strategy
Cheap generics and copycat drugs? That view of China's health sector is dangerously out of date.
Backed by Health Vision 2030, regulatory reform and significant risk capital, China's biotech ecosystem now produces novel therapies in oncology, metabolic health and AI-driven drug discovery. It is reshaping supply chains, pricing, partnerships and which therapies reach markets everywhere, and when.
Grace Lee gave members a rare inside view of a sector seldom unpacked for international audiences: how it is moving from imitation to innovation, why Western pharma now sources pipelines from China, and what that means for health strategy, vendor choices and benefit design.
What we covered- How biotech fits into China's Health Vision 2030, and the ripple effects beyond its borders
- The biggest challenges still shaping innovation, and how top firms are overcoming them
- Why Hong Kong has become the go-to listing destination for biotech
- How Chinese health companies are expanding overseas with new models and therapies
- The top areas to watch in 2026
Twelve breakfasts, twelve experts, 25 senior leaders, in the André Fu Suite at Upper House.
Book a discovery call.
Tell us about your organisation and what you have in mind. We'll scope the right programme for your business, insurance book or workforce.